This study aimed to evaluate the spectrum of karyotype abnormalities and neonatal outcome of 93 fetuses with CH from a single center in the Northern region of Turkey.
pAtiEnts And MEthods
The study covered the period between January 2010 and October 2016. All pregnant women with fetal CH referred to our genetic department were included in the study. The diagnosis of fetal CH was made by repeated fetal ultrasound examinations [ Figures 1-3 ]. The basic criteria for the description of CH were the occurrence of increased fetal nuchal translucency with excess fluid and one or more septations with an intact skull and spinal column. Fetuses with only nuchal translucency, but absent septations were not included in this study. Couples were routinely offered fetal karyotyping and genetic counseling after CH diagnosis.
Karyotypes were obtained from either amniotic cells or chorionic villi samplings (CVS) by standard procedures. For amniocentesis, along term culture method and for CVS, 24 h incubation method using BIO-AMF culture medium was applied. [12] For amniocentesis, a long-term culture method and for CVS, both 24 h incubation and a long-term method were applied using BIO-AMF culture medium. [12] After the preparation, chromosomes were GTG banded and analyzed under the optical microscope Olympus BX-51, linked to an automated imaging system (The CytoVision® Version 7.2 Image Analysis and Capture System is a rapid metaphase finder, image acquisition and computer aided chromosome analysis system).
Apart from CH, any other fetal abnormalities associated were recorded, including hydrops fetalis. Fetal hydrops was defined as an excess of subcutaneous fluid in >1 fetal area, including thorax and peritoneal cavity. An autopsy was routinely offered to these couples. Pregnancy outcomes were recorded as elective termination, misscarriage, intrauterine death (stillbirth), live birth, and neonatal death. Clinical data were obtained from patients' medical records.
In brief, other evaluated parameters were fetal age and gender, maternal age, the age of pregnancy, fetal ultrasound findings, types of fetal malformations, fetal karyotypes, and fetal outcome.
rEsults
During the study period, 3805 pregnancies were tested for fetal karyotype for reasons mainly of fetal ultrasound anomaly, advanced maternal age or high-risk triple screening test. Ninety-three out of 3805 pregnancies were recorded as fetal CH (2.5%). The average gestational age at referral to our genetic center was 16.2 weeks (range 12-23 weeks), and only 16% of pregnancies were in the first trimester. None of the 93 mothers had a previous history of CH in their medical history.
The gender of the fetus was determined by karyotype. There were 48 female and 45 male fetuses. The range of maternal age was between 16 (only one patient) and 50 years. The median maternal age was 29 ± 6.5 and was slightly lower than the age of general pregnancy population (32 ± 6.5). The median maternal age for isolated CH pregnancies was 29.5 ± 7, and for ACH (CH with other anomalies), it was 27.6 ± 5.9.
Forty-nine cases out of 93 fetal CH were isolated (ICH), and hence, no associated congenital abnormalities were detected. were terminated due to MCA (14) or ICH (8) . There were eight (8.6%) miscarriages, of which three were with hydrops and one was ACH presenting intracardiac hyperechogenic intensity. The rest four cases presented isolated CH with no karyotype anomaly. 12 pregnancies (13%) were able to reach the term. We do not have any information about the outcome of four pregnancies. Table 3 summarizes the outcome of fetuses within the study group.
Elective termination of pregnancies covered mostly (68%) CH with abnormal karyotype. 22 out of 39 fetuses with normal karyotype were also terminated. The outcome of fetuses with karyotype anomalies and with a normal karyotype is documented in Tables 4 and 5 . Overall, survival with normal pediatric outcome was confirmed in only 3% of cases.
disCussion
CHs are vascular-lymphatic malformations. They arise from the failure of the lymphatic system to communicate with the venous system in the neck. The lymphatic system begins to develop at the 6 th week, approximately 2 weeks after the Forty-four fetal CH were associated with other sonographic anomalies (ACH). Thus, the study population presented multiple congenital anomalies (MCA) in almost half (47.3%) of the patient population. Twenty-two patients presented with associated hydrops fetalis.
Overall, the most common additional congenital anomaly was cardiac malformations (27.5%) followed by anomalies of extremities, brain, gastrointestinal system, and renal anomaly. Two fetuses presented with the single umbilical artery. One fetus was diagnosed with a probable "craniofrontonasal dysplasia." Types of anomalies observed in the study group are shown in Table 1 . In the study population (93 cases of CH), Down syndrome was the most common aneuploidy followed by monosomy X, trisomy 18, and trisomy 13. Thirty-nine out of 93 fetuses showed no chromosomal abnormality, and for 18 out of the 39, no structural abnormalities were observed in addition to normal karyotype.
69 out of 93 (74%) pregnancies were terminated due to either fetal abnormality or karyotype anomaly or both. Fourty-seven out of 69 (68%) terminations were due to chromosomal abnormality. 22 (31.8%) patients with normal karyotype development of the recognizable primitive cardiovascular system. In the 8 th week of gestation, six lymphatic sacs are identified in the developing embryo. Finally, the lymphatic sacs communicate with the venous system. Ultrasonographic diagnosis of CH is usually obtained in the first trimester and the lesion can appear in septated or nonseptated forms. [13] More than 80% of pregnancies affected by CH will result in an abnormal outcome, including chromosomal abnormalities, genetic syndromes, structural anomalies, spontaneous abortion, fetal loss, or neonatal death. [8] Most cases of chromosome anomalies are aneuploidies such as Turner syndrome, Down syndrome, Klinefelter syndrome, and trisomy 18 and 13. [13] Similar to the literature data, this study shows a high rate of aneuploidy among fetuses with CH. The incidence of abnormal karyotype in our series (58%) is relatively higher than many previous reports [8, 9, 14] but similar to some others. [15, 16] Few reports were with higher rates. [17, 18] Trisomy 21, monosomy X, trisomy 18, and trisomy 13 observed as the main aneuploidies. Moreover, one patient showed double trisomy (48, XXY, inv [9] [p11q12], +21, Klinefelter syndrome and trisomy 21). To the best of our knowledge, this is the first double trisomy reported in fetal CH. Another fetus showed one regular 47, XXY and one was with a Robertsonian translocation type trisomy 13 (46, XY, +13, rob [13;14] ), the only structural abnormality seen in our series.
Aneuploidy is defined as a karyotype that results in an unbalanced genome with different copy numbers of chromosomes. Studies of aneuploidy across several species have shown that aneuploidy is frequently lethal early in the development and that those karyotypes that are not lethal usually have substantial developmental defects. There seems to be also altered gene expression levels and altered metabolism in aneuploid cells. [19] [20] [21] Deviation from a balanced genome by either gain or loss of entire chromosomes is generally tolerated poorly in all eukaryotic systems studied to date. [21] Loss of genetic information due to monosomies is less well-tolerated than the gain of genetic information due to trisomies. Autosomal monosomies are inviable in humans. However, aneuploidies of the sex chromosomes in humans are viable. Turner syndrome (monosomy X) is the only whole chromosomal monosomy viable in humans. [20] In spite of all the information given up to date, there is still limited information about the biological impact of aneuploidy during the embryonic development of fetal CH or about the genes involved in CH. Garabedian et al., reported a prenatally detected CH which was subsequently identified to have haploinsufficiency of the FOXF1 and FOXC2 genes via array comparative genomic hybridization (aCGH). [22] Fox genes are involved in patterning early embryonic mesoderm. The region encoding for the FOX gene cluster is in 16q24.1 and deletions of this region have been associated with multiple structural anomalies, including cardiopulmonary anomalies No data 3 ICH: Isolated cystic hygroma, ACH: CH and other anomalies and congenital alveolar capillary dysplasia with misalignment of the pulmonary veins. [22, 23] NS is one of the leading causes of CH. Approximately, 50% of NS cases are caused by mutations in the PTPN11 gene. [24] Molecular studies suggest that vascular endothelial growth factor C and its receptors may play an important role in the development of CHs. [25] Due to possible gene dosage effect of aneuploidies, we suggest that the development of some fetal CH is under the control of >1 gene. This oligogenic or multigenic situation is similar to the pattern seen in complex genetic disorders. Because of seldom autosomal monosomic impact, the gene dose influence ought to be in the range of overdosage of autosomal genes. Both cumulative effects and individual genes seem to be responsible for the complex phenotype of the disease. It is also possible that new diagnostic approaches such as microarray-based comparative genomic hybridization (aCGH) can help to the identification of new CH genes by means of identifications of both genomic gains or losses.
Several nonchromosomal disorders, including NS, Fryns syndrome, multiple pterygium syndrome, and achondroplasia, are also associated with an increased incidence of CH. They are clues for major gene involvement in disease development. Intrauterine alcohol exposure and viral infections have also been associated with the development of CH. [26] One can assume that more genes associated with CH will be discovered in time.
Retrospective studies suggest that CH is associated with poor prognosis. CH often causes fetal death. A study by Lajeunesse et al. involving 69 fetuses with CH diagnosed in the first trimester suggested that the presence of hydrops fetalis, ultrasonographic abnormalities or both were predictors of a poor outcome as well as karyotype abnormalities. [27] Even in euploid pregnancies with CH, there is high mortality with associated abnormalities. A study by Sanhal et al. similarly found that fetuses with septated CH had poor perinatal outcomes. [11] In this study, 74% of all pregnancies were terminated due to either fetal abnormality or karyotype anomaly or both. Most of the fetuses (68%) presenting an aberrated chromosome were electively terminated by family consent. There were eight (8.6%) miscarriages. Nearly 50% of these miscarriages were due to severe hydrops fetalis, one was with ACH, and three revealed normal karyotype with isolated CH.
Although a few patients with fetal CH could show complete spontaneous resolution. These pregnancies present often in late pregnancy and are mostly those with normal chromosomes. The fetus is unlikely to have a chromosomal abnormality if the CH goes away by week 20. In the present study, 13% of pregnancies were able to reach the term. The mean age of pregnancy for these cases in the present study was 16 weeks. The normal pediatric outcome was confirmed in only 3% of fetal CH cases. In these cases, cysts in the neck disappeared by ultrasound on follow-up of pregnancy, and there was no need to intervene after delivery.
Even in euploid pregnancies with CH, there is high mortality with associated abnormalities. In the present study within the group of CH with normal karyotype, similar poor outcome was achieved; 69% of CH fetuses with a normal karyotype were terminated due to either ICH or ACH. When spontaneous abortions and neonatal death were considered, the rate of fetal loss in this series reached up to 79%. It should be kept in mind that CH associated with a normal karyotype can also be inherited as an autosomal recessive trait. No recurrence of CH was obtained in our series.
ConClusion
CH is a clear indication for prenatal diagnosis and genetic counseling. We suggest to follow-up pregnancies with CH by periodic ultrasound examinations for resolution of the CH and/or development of other anomalies, including hydrops and to karyotype each fetus with fetal CH. In case of a normal fetal chromosome set, if there have associated anomalies, chromosomal array, or next-generation sequencing may help discover subtle chromosomal anomalies or genetic syndromes and understanding the genetic contribution to disease.
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